<VariationArchive VariationID="9767" VariationName="NM_021083.4(XK):c.1013del (p.Phe338fs)" VariationType="Deletion" Accession="VCV000009767" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-03-17" DateCreated="2016-10-13" MostRecentSubmission="2024-03-16">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="24806" VariationID="9767">
      <GeneList>
        <Gene Symbol="XK" FullName="X-linked Kx blood group antigen, Kell and VPS13A binding protein" GeneID="7504" HGNC_ID="HGNC:12811" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xp21.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="37685791" stop="37732130" display_start="37685791" display_stop="37732130" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="37545132" stop="37591382" display_start="37545132" display_stop="37591382" Strand="+" />
          </Location>
          <OMIM>314850</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_021083.4(XK):c.1013del (p.Phe338fs)</Name>
      <CanonicalSPDI>NC_000023.11:37728136:TTTT:TTT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xp21.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="37728137" stop="37728137" display_start="37728137" display_stop="37728137" variantLength="1" positionVCF="37728136" referenceAlleleVCF="CT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="37587390" stop="37587390" display_start="37587390" display_stop="37587390" variantLength="1" positionVCF="37587389" referenceAlleleVCF="CT" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>F338fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_812" sequenceAccession="LRG_812">
            <Expression>LRG_812:g.47261del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_812t1" sequenceAccession="LRG_812t1">
            <Expression>LRG_812t1:c.1013del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_812p1" sequenceAccession="LRG_812p1" change="p.Phe338fs">
            <Expression>LRG_812p1:p.Phe338fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.37587393del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.37587393del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.37728140del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.37728140del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007473.3" sequenceAccession="NG_007473" sequenceVersion="3" change="g.47261del">
            <Expression>NG_007473.3:g.47261del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_021083.4" sequenceAccession="NM_021083" sequenceVersion="4" change="c.1013del" MANESelect="true">
            <Expression>NM_021083.4:c.1013del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_066569.1" sequenceAccession="NP_066569" sequenceVersion="1" change="p.Phe338fs">
            <Expression>NP_066569.1:p.Phe338fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="314850.0004" DB="OMIM" />
        <XRef Type="rs" ID="1602159120" DB="dbSNP" />
      </XRefList>
      <Comment DataSource="ClinGen" Type="public">ClinGen staff contributed the HGVS expression for this variant.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_021083.4(XK):c.1013del (p.Phe338fs) AND McLeod neuroacanthocytosis syndrome" Accession="RCV000010421" Version="4">
        <ClassifiedConditionList TraitSetID="2723">
          <ClassifiedCondition DB="MedGen" ID="C0398568">McLeod neuroacanthocytosis syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1999-05-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1999-05-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2016-10-13" MostRecentSubmission="2024-03-16">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10426139</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2723" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10628" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">NEUROACANTHOCYTOSIS, MCLEOD TYPE</ElementValue>
                <XRef Type="MIM" ID="300842" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MCLEOD PHENOTYPE</ElementValue>
                <XRef Type="MIM" ID="300842" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">McLeod neuroacanthocytosis syndrome</ElementValue>
                <XRef ID="McLeod+neuroacanthocytosis+syndrome/8791" DB="Genetic Alliance" />
                <XRef ID="MONDO:0018945" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">McLeod syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">X-linked McLeod syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MCLDS</ElementValue>
                <XRef Type="MIM" ID="300842" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">McLeod neuroacanthocytosis syndrome (designated as MLS throughout this review) is a multisystem disorder with central nervous system (CNS), neuromuscular, cardiovascular, and hematologic manifestations in males: CNS manifestations are a neurodegenerative basal ganglia disease including movement disorders, cognitive alterations, and psychiatric symptoms. Neuromuscular manifestations include a (mostly subclinical) sensorimotor axonopathy and muscle weakness or atrophy of different degrees. Cardiac manifestations include dilated cardiomyopathy, atrial fibrillation, and tachyarrhythmia. Hematologically, MLS is defined as a specific blood group phenotype (named after the first proband, Hugh McLeod) that results from absent expression of the Kx erythrocyte antigen and weakened expression of Kell blood group antigens. The hematologic manifestations are red blood cell acanthocytosis and compensated hemolysis. Alloantibodies in the Kell and Kx blood group system can cause strong reactions to transfusions of incompatible blood and severe anemia in affected male newborns of Kell-negative mothers. Females heterozygous for XK pathogenic variants have mosaicism for the Kell and Kx blood group antigens. Although they usually lack CNS and neuromuscular manifestations, some heterozygous females may develop clinical manifestations including chorea or late-onset cognitive decline.</Attribute>
                <XRef ID="NBK1354" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000500117" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509072" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509486" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000511451" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10731" />
                <XRef ID="10731" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301528</ID>
                <ID Source="BookShelf">NBK1354</ID>
              </Citation>
              <XRef ID="59306" DB="Orphanet" />
              <XRef ID="C0398568" DB="MedGen" />
              <XRef ID="MONDO:0018945" DB="MONDO" />
              <XRef Type="MIM" ID="300842" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="30647" SubmissionDate="2016-10-10" DateLastUpdated="2024-03-16" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="314850.0004_MCLEOD SYNDROME" title="XK, 1-BP DEL, 1095T_MCLEOD SYNDROME" />
        <ClinVarAccession Accession="SCV000030647" DateUpdated="2024-03-16" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1999-05-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a 50-year-old Japanese man with McLeod syndrome (MCLDS; 300842), Hanaoka et al. (1999) found deletion of a single base, T, at nucleotide 1095 of the XK gene (codon 320), which was predicted to cause a premature stop codon at amino acid 408. His 82-year-old mother was heterozygous for the mutation and had no neuromuscular symptoms and normal serum creatine kinase levels. The man had noticed slowly progressive muscular atrophy, weakness in the lower limbs, and gait disturbance since the age of 45. At the age of 26, he had been hospitalized for depression, and high levels of serum transaminase and creatine kinase were noted.</Attribute>
              <Citation>
                <ID Source="PubMed">10426139</ID>
              </Citation>
              <XRef DB="OMIM" ID="300842" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="XK" />
          </GeneList>
          <Name>XK, 1-BP DEL, 1095T</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP DEL, 1095T</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="314850.0004" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">MCLEOD SYNDROME</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="30647" TraitType="Disease" MappingType="Name" MappingValue="MCLEOD SYNDROME" MappingRef="Preferred">
        <MedGen CUI="C0398568" Name="McLeod neuroacanthocytosis syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

